Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab

Gemma Bruera, Katia Cannita, Felice Giuliante, Paola Lanfiuti Baldi, Roberto Vicentini, Paolo Marchetti, Gennaro Nuzzo, Adelmo Antonucci, Corrado Ficorella, Enrico Ricevuto

Research output: Contribution to journalArticle

Abstract

Background: Intensive medical treatment increases resection rate of liver metastases in patients with metastatic colorectal cancer (MCRC). The effectiveness of liver metastasectomies was evaluated in patients with MCRC who were treated with previously reported FIr-B/FOx (triplet chemotherapy plus bevacizumab). Patients and Methods: Fifty patients with MCRC enrolled in the reported phase II study were classified according to involved metastatic sites (liver-only metastatic site, multiple metastatic sites) and the extent of liver metastases (single, multiple). Surgical resectability of liver metastases was evaluated at baseline and every 3 cycles of FIr-B/FOx treatment. The resection rate of liver metastases, activity, and efficacy were evaluated; progression-free survival (PFS) and overall survival (OS) were compared by using the log-rank test. Results: Patients with liver MCRC were 33 of 50 consecutive unselected patients with MCRC: liver limited, 22 patients; multiple metastatic sites, 11 patients. Liver metastasectomies were performed in 13 patients: 26% of 50 patients with MCRC, 39% of 33 patients with liver MCRC. In patients with liver-only MCRC, a secondary liver surgery was performed in 54%: 6 of 9 single and 6 of 13 multiple liver metastases. Also, 1 liver and lung metastasectomy was performed. Pathologic complete responses were achieved in 2 patients (15%). The conversion rate of unresectable liver metastases was 83%. Objective response rate, PFS, OS were, respectively: 84%, 11 and 23 months in 33 liver MCRC; 86%, 17 and 44 months in 22 liver-limited patients. PFS and OS were significantly increased in patients with liver-limited metastases compared with multiple metastatic sites and single compared with multiple liver metastases. Conclusion: The FIr-B/FOx regimen may increase the resection rate of liver metastases and improve clinical outcome of patients with liver-only MCRC.

Original languageEnglish
Pages (from-to)119-126
Number of pages8
JournalClinical Colorectal Cancer
Volume11
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Metastasectomy
Colorectal Neoplasms
Drug Therapy
Liver
Neoplasm Metastasis
Bevacizumab
Disease-Free Survival
Survival

Keywords

  • Integrated treatments
  • Intensive chemotherapy
  • Liver limited
  • Liver only
  • Liver surgery

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. / Bruera, Gemma; Cannita, Katia; Giuliante, Felice; Baldi, Paola Lanfiuti; Vicentini, Roberto; Marchetti, Paolo; Nuzzo, Gennaro; Antonucci, Adelmo; Ficorella, Corrado; Ricevuto, Enrico.

In: Clinical Colorectal Cancer, Vol. 11, No. 2, 2012, p. 119-126.

Research output: Contribution to journalArticle

Bruera, G, Cannita, K, Giuliante, F, Baldi, PL, Vicentini, R, Marchetti, P, Nuzzo, G, Antonucci, A, Ficorella, C & Ricevuto, E 2012, 'Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab', Clinical Colorectal Cancer, vol. 11, no. 2, pp. 119-126. https://doi.org/10.1016/j.clcc.2011.11.002
Bruera, Gemma ; Cannita, Katia ; Giuliante, Felice ; Baldi, Paola Lanfiuti ; Vicentini, Roberto ; Marchetti, Paolo ; Nuzzo, Gennaro ; Antonucci, Adelmo ; Ficorella, Corrado ; Ricevuto, Enrico. / Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. In: Clinical Colorectal Cancer. 2012 ; Vol. 11, No. 2. pp. 119-126.
@article{f063a5433e73465eb358ceb17e3aa9e0,
title = "Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab",
abstract = "Background: Intensive medical treatment increases resection rate of liver metastases in patients with metastatic colorectal cancer (MCRC). The effectiveness of liver metastasectomies was evaluated in patients with MCRC who were treated with previously reported FIr-B/FOx (triplet chemotherapy plus bevacizumab). Patients and Methods: Fifty patients with MCRC enrolled in the reported phase II study were classified according to involved metastatic sites (liver-only metastatic site, multiple metastatic sites) and the extent of liver metastases (single, multiple). Surgical resectability of liver metastases was evaluated at baseline and every 3 cycles of FIr-B/FOx treatment. The resection rate of liver metastases, activity, and efficacy were evaluated; progression-free survival (PFS) and overall survival (OS) were compared by using the log-rank test. Results: Patients with liver MCRC were 33 of 50 consecutive unselected patients with MCRC: liver limited, 22 patients; multiple metastatic sites, 11 patients. Liver metastasectomies were performed in 13 patients: 26{\%} of 50 patients with MCRC, 39{\%} of 33 patients with liver MCRC. In patients with liver-only MCRC, a secondary liver surgery was performed in 54{\%}: 6 of 9 single and 6 of 13 multiple liver metastases. Also, 1 liver and lung metastasectomy was performed. Pathologic complete responses were achieved in 2 patients (15{\%}). The conversion rate of unresectable liver metastases was 83{\%}. Objective response rate, PFS, OS were, respectively: 84{\%}, 11 and 23 months in 33 liver MCRC; 86{\%}, 17 and 44 months in 22 liver-limited patients. PFS and OS were significantly increased in patients with liver-limited metastases compared with multiple metastatic sites and single compared with multiple liver metastases. Conclusion: The FIr-B/FOx regimen may increase the resection rate of liver metastases and improve clinical outcome of patients with liver-only MCRC.",
keywords = "Integrated treatments, Intensive chemotherapy, Liver limited, Liver only, Liver surgery",
author = "Gemma Bruera and Katia Cannita and Felice Giuliante and Baldi, {Paola Lanfiuti} and Roberto Vicentini and Paolo Marchetti and Gennaro Nuzzo and Adelmo Antonucci and Corrado Ficorella and Enrico Ricevuto",
year = "2012",
doi = "10.1016/j.clcc.2011.11.002",
language = "English",
volume = "11",
pages = "119--126",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab

AU - Bruera, Gemma

AU - Cannita, Katia

AU - Giuliante, Felice

AU - Baldi, Paola Lanfiuti

AU - Vicentini, Roberto

AU - Marchetti, Paolo

AU - Nuzzo, Gennaro

AU - Antonucci, Adelmo

AU - Ficorella, Corrado

AU - Ricevuto, Enrico

PY - 2012

Y1 - 2012

N2 - Background: Intensive medical treatment increases resection rate of liver metastases in patients with metastatic colorectal cancer (MCRC). The effectiveness of liver metastasectomies was evaluated in patients with MCRC who were treated with previously reported FIr-B/FOx (triplet chemotherapy plus bevacizumab). Patients and Methods: Fifty patients with MCRC enrolled in the reported phase II study were classified according to involved metastatic sites (liver-only metastatic site, multiple metastatic sites) and the extent of liver metastases (single, multiple). Surgical resectability of liver metastases was evaluated at baseline and every 3 cycles of FIr-B/FOx treatment. The resection rate of liver metastases, activity, and efficacy were evaluated; progression-free survival (PFS) and overall survival (OS) were compared by using the log-rank test. Results: Patients with liver MCRC were 33 of 50 consecutive unselected patients with MCRC: liver limited, 22 patients; multiple metastatic sites, 11 patients. Liver metastasectomies were performed in 13 patients: 26% of 50 patients with MCRC, 39% of 33 patients with liver MCRC. In patients with liver-only MCRC, a secondary liver surgery was performed in 54%: 6 of 9 single and 6 of 13 multiple liver metastases. Also, 1 liver and lung metastasectomy was performed. Pathologic complete responses were achieved in 2 patients (15%). The conversion rate of unresectable liver metastases was 83%. Objective response rate, PFS, OS were, respectively: 84%, 11 and 23 months in 33 liver MCRC; 86%, 17 and 44 months in 22 liver-limited patients. PFS and OS were significantly increased in patients with liver-limited metastases compared with multiple metastatic sites and single compared with multiple liver metastases. Conclusion: The FIr-B/FOx regimen may increase the resection rate of liver metastases and improve clinical outcome of patients with liver-only MCRC.

AB - Background: Intensive medical treatment increases resection rate of liver metastases in patients with metastatic colorectal cancer (MCRC). The effectiveness of liver metastasectomies was evaluated in patients with MCRC who were treated with previously reported FIr-B/FOx (triplet chemotherapy plus bevacizumab). Patients and Methods: Fifty patients with MCRC enrolled in the reported phase II study were classified according to involved metastatic sites (liver-only metastatic site, multiple metastatic sites) and the extent of liver metastases (single, multiple). Surgical resectability of liver metastases was evaluated at baseline and every 3 cycles of FIr-B/FOx treatment. The resection rate of liver metastases, activity, and efficacy were evaluated; progression-free survival (PFS) and overall survival (OS) were compared by using the log-rank test. Results: Patients with liver MCRC were 33 of 50 consecutive unselected patients with MCRC: liver limited, 22 patients; multiple metastatic sites, 11 patients. Liver metastasectomies were performed in 13 patients: 26% of 50 patients with MCRC, 39% of 33 patients with liver MCRC. In patients with liver-only MCRC, a secondary liver surgery was performed in 54%: 6 of 9 single and 6 of 13 multiple liver metastases. Also, 1 liver and lung metastasectomy was performed. Pathologic complete responses were achieved in 2 patients (15%). The conversion rate of unresectable liver metastases was 83%. Objective response rate, PFS, OS were, respectively: 84%, 11 and 23 months in 33 liver MCRC; 86%, 17 and 44 months in 22 liver-limited patients. PFS and OS were significantly increased in patients with liver-limited metastases compared with multiple metastatic sites and single compared with multiple liver metastases. Conclusion: The FIr-B/FOx regimen may increase the resection rate of liver metastases and improve clinical outcome of patients with liver-only MCRC.

KW - Integrated treatments

KW - Intensive chemotherapy

KW - Liver limited

KW - Liver only

KW - Liver surgery

UR - http://www.scopus.com/inward/record.url?scp=84860740352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860740352&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2011.11.002

DO - 10.1016/j.clcc.2011.11.002

M3 - Article

C2 - 22206922

AN - SCOPUS:84860740352

VL - 11

SP - 119

EP - 126

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -